Clinical Trial Update: Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating TAK-058 and ondansetron on P50 auditory gating in participants with stable schizophrenia; the trial was terminated with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Ondansetron (ondansetron)
• TAK-058 (ENV8058)

Snippet

Sponsor: Takeda | Conditions: Schizophrenia | Phase 1 | Status: TERMINATED | Results posted: 2017-05-01